Last year, Double Bond Pharmaceutical and Laboratoire XO signed a distribution agreement for Inofer in Sweden, Norway, Denmark and Finland. Now Double Bond Pharmaceutical has the distribution rights for Russia and Belarus as well. Inofer is an iron supplement consisting of ferrous succinate which is a chemical iron form known to be more readily absorbed into the body of people with impaired iron uptake. According to WHO, "iron deficiency is the most common and widespread nutritional disorder in the world". Inofer is registered in France. The results of DBP"s clinical trial of Inofer showed a marked improvement and significant iron uptake, iron saturation and iron stores in patients with heart failure and iron deficiency.

"Now that Inofer proved to be effective in the latest clinical trial, we strongly believe in a great market potential for the product," comments the CEO of Double Bond Pharmaceutical AB Igor Lokot. - We are very happy to get rights for Inofer even for the largest country in the world”

More about previous agreements with Laboratoire XO: https://mb.cision.com/Main/12720/2445250/787980.pdf

More about DBP"s clinical trial: https://mb.cision.com/Main/12720/2974295/1151389.pdf

More about Drugsson AB: www.drugsson.com

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 2nd of December 2019.

___________________________________________________________________ 

Full Company Name:   Double Bond Pharmaceutical International AB (publ)

Corporate identity:       556991-6082

Stock short name:       DBP B

Share ISIN code:         SE0007185525

For more info, contact

Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com

Follow us on LinkedIn (https://www.linkedin.com/company/double-bond-pharmaceutical?trk=co-feed-likes-one) and Twitter (https://twitter.com/DoubleBondPharm)!

_______________________________________________________________________________

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. 

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.